載入...
Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer
BACKGROUND: Targeting growth factor and survival pathways may delay endocrine-resistance in estrogen receptor-positive breast cancer. MATERIALS & METHODS: A pilot Phase II study adding sorafenib to endocrine therapy in 11 patients with metastatic estrogen receptor-positive breast cancer was cond...
Na minha lista:
| 發表在: | Future Oncol |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5527710/ https://ncbi.nlm.nih.gov/pubmed/24826798 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon.14.99 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|